Who has been buying Quad Medicine stock?

2 distinct insiders have filed 8 disclosed insider purchases in Quad Medicine (464490), most recently on 2026-06-15. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Quad Medicine have?

Quad Medicine has 8 buy-side and 0 sell-side disclosures on record, covering ₩379M ($263K) in total reported value, spanning 2025-12-12 to 2026-06-15.

Where does StockDrifts get Quad Medicine insider data?

From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Quad Medicine 464490

Company

쿼드메디슨Quad Medicine

Insiders

Buys

Total Value

₩379M ($263K)

Avg Return

+1.77%

Last Filing

2026-06-15

Quad Medicine (464490) has 8 disclosed insider purchases and 0 disclosed disposals on record, filed by 2 distinct insiders. Together those filings cover ₩379M ($263K) in reported transaction value. The earliest filing StockDrifts holds for Quad Medicine is dated 2025-12-12; the most recent is 2026-06-15. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is +1.77%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-07-22	BUY	Market Buy	백승기 Baek Seung-gi	CEO	670	₩5,500	+3.8%	₩4M ($3K)
2026-07-21	BUY	Market Buy	백승기 Baek Seung-gi	CEO	1.2K	₩5,620	+1.6%	₩7M ($5K)
2026-07-20	BUY	Market Buy	백승기 Baek Seung-gi	CEO	3.5K	₩5,940	-3.9%	₩21M ($14K)
2026-07-16	BUY	Market Buy	백승기 Baek Seung-gi	CEO	1.8K	₩6,000	-4.8%	₩11M ($8K)
2026-07-15	BUY	Market Buy	백승기 Baek Seung-gi	CEO	3.0K	₩5,800	-1.6%	₩17M ($12K)
2026-07-14	BUY	Market Buy	백승기 Baek Seung-gi	CEO	5.2K	₩5,400	+5.7%	₩28M ($20K)
2026-06-15	BUY	Market Buy	백승기 Baek Seung-gi	CEO	149	₩7,730	+0.0%	₩1M ($800)
2026-06-12	BUY	Market Buy	백승기 Baek Seung-gi	CEO	1.7K	₩7,800	-0.9%	₩14M ($9K)
2026-06-11	BUY	Market Buy	백승기 Baek Seung-gi	CEO	1.9K	₩7,780	-0.6%	₩15M ($10K)
2026-06-10	BUY	Market Buy	백승기 Baek Seung-gi	CEO	10.0K	₩7,880	-1.9%	₩79M ($55K)
2026-06-09	BUY	Market Buy	백승기 Baek Seung-gi	CEO	11.4K	₩7,630	+1.3%	₩87M ($60K)
2026-04-24	BUY	Market Buy	백승기 Baek Seung-gi	CEO	6.0K	₩13,230	+4.3%	₩79M ($55K)
2026-04-23	BUY	Market Buy	백승기 Baek Seung-gi	CEO	4.0K	₩13,020	+6.0%	₩52M ($36K)
2026-04-23	BUY	Market Buy	김영흥 Youngheung Kim	moving	4.0K	₩13,020	+6.0%	₩53M ($37K)
2026-02-02	SELL	기타	성길환 Seong Gil-hwan	moving	-13.5K	₩15,000	-15.3%	₩203M ($141K)
2026-02-02	BUY	주식매수선택권	김영흥 Youngheung Kim	moving	18.0K	₩15,000	+15.3%	₩270M ($188K)
2026-02-02	SELL	기타	김영흥 Youngheung Kim	moving	-18.0K	₩15,000	-15.3%	₩270M ($188K)
2026-02-02	BUY	주식매수선택권	성길환 Seong Gil-hwan	moving	13.5K	₩15,000	+15.3%	₩203M ($141K)
2026-02-01	BUY	신규선임	조현종 Hyeonjong Cho	moving	10.0K	₩15,000	+15.3%	₩150M ($104K)
2026-01-01	BUY	신규선임	나운성 Naunseong	moving	25.2K	₩14,500	+19.3%	₩365M ($254K)
2025-12-31	SELL	임원퇴임	허혜진 Hyejin Heo	moving	-5.9K	₩14,500	-19.3%	₩85M ($59K)
2025-12-12	BUY	PROGRAM	황근배 Hwang Geun-bae	moving	10.0K	₩17,630	-1.9%	₩176M ($122K)
2025-12-12	BUY	PROGRAM	허혜진 Hyejin Heo	moving	5.9K	₩17,630	-1.9%	₩104M ($72K)
2025-12-12	BUY	PROGRAM	박정환 Park Jeong-hwan	CTO	441.0K	₩17,630	-1.9%	₩7.8B ($5.4M)
2025-12-12	BUY	신규상장	성길환 Seong Gil-hwan	moving	66.8K	₩17,630	-1.9%	₩1.2B ($818K)
2025-12-12	BUY	신규상장	성길환 Seong Gil-hwan	moving	13.5K	₩17,630	-1.9%	₩238M ($165K)
2025-12-12	BUY	PROGRAM	백승기 Baek Seung-gi	CEO	2.2M	₩17,630	-1.9%	₩38.5B ($26.7M)
2025-12-12	BUY	PROGRAM	현신애 Hyun Shin-ae	moving	48.3K	₩17,630	-1.9%	₩852M ($591K)
2025-12-12	BUY	PROGRAM	김영흥 Youngheung Kim	moving	18.0K	₩17,630	-1.9%	₩317M ($220K)
2025-12-12	BUY	PROGRAM	전혜선 Jeon Hye-sun	moving	52.5K	₩17,630	-1.9%	₩926M ($643K)
2025-12-12	BUY	PROGRAM	김영흥 Youngheung Kim	moving	45.0K	₩17,630	-1.9%	₩793M ($551K)
2025-12-12	BUY	PROGRAM	황근배 Hwang Geun-bae	moving	10.0K	₩17,630	-1.9%	₩176M ($122K)

Frequently asked questions

Who has been buying Quad Medicine stock?: 2 distinct insiders have filed 8 disclosed insider purchases in Quad Medicine (464490), most recently on 2026-06-15. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Quad Medicine have?: Quad Medicine has 8 buy-side and 0 sell-side disclosures on record, covering ₩379M ($263K) in total reported value, spanning 2025-12-12 to 2026-06-15.
Where does StockDrifts get Quad Medicine insider data?: From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Quad Medicine. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.